Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878692 | 0.90 | FAAH (0.53) | HTR2CHTR2BHTR2AL3MBTL1MEN1 | |
| SCHEMBL9341108 | 0.87 | THRA (0.53) | HTR2BL3MBTL1MEN1ALDH1A1KMT2A | |
| SCHEMBL6790486 | 0.84 | HTR2C (0.47) | HTR2CHTR2BHTR2AL3MBTL1MEN1 | |
| SCHEMBL9484389 | 0.84 | MAPT (0.46) | HTR2CHTR2BHTR2AL3MBTL1MEN1 | |
| SCHEMBL1547577 | 0.83 | L3MBTL1 (0.53) | L3MBTL1MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL21388207 | 0.83 | L3MBTL1 (0.48) | L3MBTL1MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL9340707 | 0.83 | L3MBTL1 (0.46) | L3MBTL1MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL14402360 | 0.82 | HPGD (0.47) | L3MBTL1MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL14293809 | 0.82 | MAPT (0.50) | HTR2CHTR2BHTR2AL3MBTL1MEN1 | |
| SCHEMBL14409236 | 0.82 | HTR2C (0.49) | HTR2CHTR2BHTR2AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11664093-B2 | Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
| US-7074523-B2 | Lithium secondary battery | HITACHI, LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040106039-A1 | nonaqueous electrolytic solution containing a compound that is oxidized at a voltage > a charge end voltage of the battery and a compound which inhibits reactions at voltages < the charge end voltage | ARAI JUICHI (JP) | 2004-06-03 | — | — | US | disclosed |
| US-20030003370-A1 | Nonaqueous electrolytic solution containing a compound which is oxidized at a voltage higher than a charge end voltage of the lithium secondary battery and a compound which inhibits reactions at voltages lower than said charge end voltage. | HITACHI, LTD. (JP) | 2003-01-02 | — | — | US | disclosed |
| EP-1258939-A2 | Lithium secondary battery | Hitachi, Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | HTR2C 4499/4885HTR2B 4001/4885HTR2A 4229/4885 |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | HTR2C 4499/4885HTR2B 4001/4885HTR2A 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.